Intravenous immunoglobulin (IVIG) therapy is an important treatment for fetal and neonatal alloimmune thrombocytopenia (FNAIT), and a review published recently in Archives of Disease in Childhood-Fetal and Neonatal Edition described how IVIG can dramatically reduce the risk of severe bleeding, including intracranial hemorrhage, particularly when used during pregnancy in high-risk cases.
FNAIT occurs when a mother develops immunoglobulin G antibodies against platelet antigens inherited from the father and present on the fetus’s platelets. These maternal antibodies cross the placenta and mark fetal platelets for destruction. Because maternal immunoglobulin G can remain in a newborn’s circulation for up to six months after birth, the immune attack can continue during the neonatal period. The resulting low platelet counts increase the risk of serious bleeding complications, especially bleeding in the brain.
IVIG therapy is widely used to manage this immune process. The treatment contains purified immunoglobulin G antibodies pooled from thousands of plasma donors. When infused intravenously, these antibodies help disrupt the harmful immune response responsible for FNAIT. IVIG can block immune receptors involved in platelet destruction, neutralize harmful antibodies and accelerate the removal of pathogenic maternal antibodies from circulation. These actions reduce the immune system’s ability to destroy fetal and neonatal platelets.
Learn more about FNAIT treatment and care
For pregnancies at high risk of FNAIT, IVIG is often the first-line antenatal therapy. Weekly IVIG treatment at 1 g/kg beginning between 12 and 20 weeks of gestation is recommended for pregnancies with a previous child affected by intracranial hemorrhage. In pregnancies considered standard risk, therapy typically begins between 20 and 24 weeks. Studies have shown that this approach prevents intracranial hemorrhage in more than 95% of fetuses.
After birth, IVIG also plays a role in the treatment of infants with FNAIT. However, platelet transfusion remains the primary therapy because it raises platelet levels more quickly. IVIG is frequently given alongside matched or unmatched platelet transfusions to help stabilize platelet counts and prolong the benefit of transfusion therapy. On its own, IVIG may take 24 to 48 hours to significantly increase platelet levels.
For patients and families affected by FNAIT, these treatments have improved outcomes considerably. IVIG has reduced the need for more invasive procedures such as fetal blood sampling or intrauterine platelet transfusions, which carry complication rates of about 11% per treated pregnancy. Although IVIG is generally safe, clinicians still weigh potential side effects such as allergic reactions, kidney injury or other infusion-related complications. Even so, the therapy remains a cornerstone of care while researchers continue developing more targeted treatments for immune-mediated fetal conditions such as FNAIT.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
